Poxel SA: Poxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting 2022
Late-breaking abstract selected by AASLD as one of the "Best of the Liver Meeting" for 2022 Phase 2 for PXL065 in NASH achieved the primary efficacy endpoint for liver fat content reduction
Source: finanznachrichten.de